JP2016504369A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504369A5
JP2016504369A5 JP2015550818A JP2015550818A JP2016504369A5 JP 2016504369 A5 JP2016504369 A5 JP 2016504369A5 JP 2015550818 A JP2015550818 A JP 2015550818A JP 2015550818 A JP2015550818 A JP 2015550818A JP 2016504369 A5 JP2016504369 A5 JP 2016504369A5
Authority
JP
Japan
Prior art keywords
formulation
hydrophilic polymer
type
polymer chain
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015550818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504369A (ja
JP6533932B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/078102 external-priority patent/WO2014106116A2/en
Publication of JP2016504369A publication Critical patent/JP2016504369A/ja
Publication of JP2016504369A5 publication Critical patent/JP2016504369A5/ja
Application granted granted Critical
Publication of JP6533932B2 publication Critical patent/JP6533932B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015550818A 2012-12-28 2013-12-27 抗体を含む治療用組成物 Active JP6533932B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747176P 2012-12-28 2012-12-28
US61/747,176 2012-12-28
PCT/US2013/078102 WO2014106116A2 (en) 2012-12-28 2013-12-27 Delivery of biologic therapeutics

Publications (3)

Publication Number Publication Date
JP2016504369A JP2016504369A (ja) 2016-02-12
JP2016504369A5 true JP2016504369A5 (enExample) 2017-02-09
JP6533932B2 JP6533932B2 (ja) 2019-06-26

Family

ID=50000100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015550818A Active JP6533932B2 (ja) 2012-12-28 2013-12-27 抗体を含む治療用組成物

Country Status (5)

Country Link
US (2) US9452138B2 (enExample)
EP (1) EP2938323A2 (enExample)
JP (1) JP6533932B2 (enExample)
CN (1) CN105007896B (enExample)
WO (1) WO2014106116A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
CA3010329A1 (en) * 2015-12-29 2017-07-06 Oncobiologics, Inc. Buffered formulations of bevacizumab
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック, インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
WO2020014185A1 (en) 2018-07-09 2020-01-16 Regeneron Pharmaceuticals, Inc. Tuning of release kinetics in hydrogels
WO2020041689A1 (en) * 2018-08-23 2020-02-27 Bernstein Eric F Systems, devices and methods for applying anti-vegf compounds and using such compounds to treat skin conditions
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CN121197419A (zh) * 2019-09-30 2025-12-26 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用
CN112569358B (zh) * 2019-09-30 2022-06-28 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
WO2023038463A1 (ko) * 2021-09-09 2023-03-16 선바이오(주) 6-arm peg 수화겔의 시간 경과에 따른 졸-겔 전환
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7908799A (nl) * 1978-12-22 1980-06-24 Tno Werkwijze voor de bereiding van een polymeermengsel, gevormde produkten, verkregen daaruit en polymeer- legering.
US5971953A (en) * 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
CN1569892A (zh) * 2004-04-30 2005-01-26 新峰生物科技(上海)有限公司 多臂树杈型聚乙二醇与蛋白质或多肽的结合物及其制备方法
TW200640492A (en) 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
EP2014256A1 (en) * 2007-07-12 2009-01-14 Straumann Holding AG Composite bone repair material
US8642737B2 (en) * 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
DK2699274T3 (en) * 2011-04-20 2015-06-15 Carbylan Therapeutics Inc In situ gelling formations

Similar Documents

Publication Publication Date Title
Larrañeta et al. Hydrogels for hydrophobic drug delivery. Classification, synthesis and applications
Chung et al. Self-assembled and nanostructured hydrogels for drug delivery and tissue engineering
Banerjee et al. Use of dextran nanoparticle: A paradigm shift in bacterial exopolysaccharide based biomedical applications
Pinelli et al. In vivo drug delivery applications of nanogels: a review
CN105007896B (zh) 包含抗体的治疗组合物
Coelho et al. Drug delivery systems: Advanced technologies potentially applicable in personalized treatments
CN102585303B (zh) 一种壳聚糖/聚赖氨酸原位凝胶及其制备方法
Morimoto et al. Design of hybrid hydrogels with self-assembled nanogels as cross-linkers: interaction with proteins and chaperone-like activity
AU2012224525B2 (en) Implantable bio-resorbable polymer charged with fragile macromolecules
CN103492420B (zh) 透明质酸-蛋白质结合物及其制备方法
JP6143269B2 (ja) 自己組織化複合超小型ペプチドポリマーヒドロゲル
Matricardi et al. Polysaccharide hydrogels: Characterization and biomedical applications
Drapala et al. The Effect of Glutathione as Chain Transfer Agent in PNIPAAm-Based Thermo-responsive Hydrogels for Controlled Release of Proteins: Drapala et al.
Aminabhavi et al. Production of chitosan-based hydrogels for biomedical applications
BRPI0215731B1 (pt) polímero sensível ao ph, seus usos e seu processo de preparação
Hong et al. Inherent charge-shifting polyelectrolyte multilayer blends: a facile route for tunable protein release from surfaces
CN111789810A (zh) 用于药物递送的水凝胶组合物和其用途
CN116710110A (zh) 新型的多层聚合物涂层交联海藻酸凝胶纤维
Laffleur Mucoadhesive therapeutic compositions: a patent review (2011-2014)
CN107970204A (zh) 水凝胶组合物及包含其的药物递送系统
Mohanta et al. Beyond PEGylation “PEGylation and its alternatives”
Li Polymeric hydrogels
Datea Joseph S. Adamsa, Yogesh Sutara, Sagar Dhoblea, Chiranjit Maitia, Sonali Nitin Hanjankarb, Rajeswari Dasa, Vandana Patravaleb, and
JP6556208B2 (ja) ヒドロゲル組成物およびこれを含む薬物送達システム
Pippa et al. Hydrogels as Intelligent Drug Delivery Systems